Form 8-K - Current report:
SEC Accession No. 0000950170-25-028343
Filing Date
2025-02-27
Accepted
2025-02-27 07:03:06
Documents
12
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cgem-20250227.htm   iXBRL 8-K 43889
2 EX-99.1 cgem-ex99_1.htm EX-99.1 199554
  Complete submission text file 0000950170-25-028343.txt   369431

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20250227.xsd EX-101.SCH 24922
14 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20250227_htm.xml XML 4711
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 25672939
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)